Creative Commons source reading · Neuromodulation and neural interfaces
Subthalamic and pallidal deep brain stimulation for Parkinson's disease-meta-analysis of outcomes.
M Lenard Lachenmayer; Melina Mürset; Nicolas Antih; Ines Debove; Julia Muellner; Maëlys Bompart; Janine-Ai Schlaeppi; Andreas Nowacki; Hana You; Joan P Michelis; Alain Dransart; Claudio Pollo; Guenther Deuschl; Paul Krack
Originally published in NPJ Parkinson's disease · 2021-09-06
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Although deep brain stimulation (DBS) of the globus pallidus internus (GPi) and the subthalamic nucleus (STN) has become an established treatment for Parkinson's disease (PD), a recent meta-analysis of outcomes is lacking. To address this gap, we performed a meta-analysis of bilateral STN- and GPi-DBS studies published from 1990-08/2019. Studies with ≥10 subjects reporting Unified Parkinson's Disease Rating Scale (UPDRS) III motor scores at baseline and 6-12 months follow-up were included. Several outcome variables were analyzed and adverse events (AE) were summarized. 39 STN studies (2035 subjects) and 5 GPi studies (292 subjects) were eligible. UPDRS-II score after surgery in the stimulation-ON/medication-OFF state compared to preoperative medication-OFF state improved by 47% with STN-DBS and 18.5% with GPi-DBS. UPDRS-III score improved by 50.5% with STN-DBS and 29.8% with GPi-DBS. STN-DBS improved dyskinesia by 64%, daily OFF time by 69.1%, and quality of life measured by PDQ-39 by 22.2%, while Levodopa Equivalent Daily Dose (LEDD) was reduced by 50.0%. For GPi-DBS information regarding dyskinesia, OFF time, PDQ-39 and LEDD was insufficient for further analysis.
Discussion
The aim of this article was to provide an updated review of the published literature on the outcomes of bilateral STN- and GPi-DBS for PD. According to our inclusion criteria, a majority of studies focused on the STN (n = 39) involving 1747 subjects with follow-up data and, to a much lesser extent, the GPi (n = 5) with 291 subjects with follow-up data.
Editorial reading guide
- How were patients or cases selected, and what did the authors use as a comparator?
- Which outcomes, complications and follow-up intervals determine how far the findings apply?
